Active Filter(s):
Details:
Royalty Pharma will acquire Minerva’s royalty interest in seltorexant. Seltorexant is currently in Phase 3 development for the treatment of major depressive disorder (MDD) with insomnia symptoms by Janssen Pharmaceutica, N.V., a subsidiary of Johnson & Johnson.
Lead Product(s): Seltorexant
Therapeutic Area: Psychiatry/Psychology Product Name: MIN-202
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Royalty Pharma
Deal Size: $155.0 million Upfront Cash: $60.0 million
Deal Type: Acquisition January 19, 2021
Details:
Minerva Neuroscienceshas exercised its right to opt out of its agreement with Janssen Pharmaceutica future development of seltorexant. As a result, Minerva will now collect a royalty on worldwide sales of seltorexant in all indications.
Lead Product(s): Seltorexant
Therapeutic Area: Sleep Product Name: MIN-202
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Johnson & Johnson Innovative Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 01, 2020